[1] |
Bansal S, Garg VK, Sardana K, et al. A clinicotherapeutic analysis of Stevens⁃Johnson syndrome and toxic epidermal necrolysis with an emphasis on the predictive value and accuracy of score of toxic epidermal necrolysis[J]. Int J Dermatol, 2015, 54(1): e18⁃26. DOI: 10.1111/ijd.12466.
|
[2] |
Bastuji⁃Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity⁃of⁃illness score for toxic epidermal necrolysis[J]. J Invest Dermatol, 2000, 115(2): 149⁃153. DOI: 10.1046/j.1523⁃1747.2000.00061.x.
|
[3] |
Cartotto R, Mayich M, Nickerson D, et al. SCORTEN accurately predicts mortality among toxic epidermal necrolysis patients treated in a burn center[J]. J Burn Care Res, 2008, 29(1): 141⁃146. DOI: 10.1097/BCR.0b013e31815f3865.
|
[4] |
Imahara SD, Holmes JH, Heimbach DM, et al. SCORTEN overestimates mortality in the setting of a standardized treatment protocol[J]. J Burn Care Res, 2006, 27(3): 270⁃275. DOI: 10.1097/01.BCR.0000216532.71360.9B.
|
[5] |
Bastuji⁃Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens⁃Johnson syndrome, and erythema multiforme[J]. Arch Dermatol, 1993, 129(1): 92⁃96.
|
[6] |
Sekula P, Liss Y, Davidovici B, et al. Evaluation of SCORTEN on a cohort of patients with Stevens⁃Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study[J]. J Burn Care Res, 2011, 32(2): 237⁃245. DOI: 10.1097/BCR. 0b013e31820aafbc.
|
[7] |
Vaishampayan SS, Das AL, Verma R. SCORTEN: does it need modification?[J]. Indian J Dermatol Venereol Leprol, 2008, 74(1): 35⁃37.
|
[8] |
Trent JT, Kirsner RS, Romanelli P, et al. Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States[J]. Arch Dermatol, 2004, 140(7): 890⁃892. DOI: 10.1001/archderm.140.7.890.
|
[9] |
Morales ME, Purdue GF, Verity SM, et al. Ophthalmic manifestations of Stevens⁃Johnson syndrome and toxic epidermal necrolysis and relation to SCORTEN[J]. Am J Ophthalmol, 2010, 150(4): 505⁃510.e1. DOI: 10.1016/j.ajo.2010.04.026.
|
[10] |
杨永生, 徐金华, 朱小华, 等. SCORTEN评分系统评估重症大疱性药疹的可行性分析[J]. 临床皮肤科杂志, 2011, 40(1): 19⁃20. DOI: 10.3969/j.issn.1000⁃4963.2011.01.008.
|
|
Yang YS, Xu JH, Zhu XH, et al. Performance of the SCORTEN on patients with severe bullous drug eruption[J]. J Clin Dermatol, 2011, 40(1): 19⁃20. DOI:10.3969/j.issn.1000⁃4963.2011.01.008.
|
[11] |
Guégan S, Bastuji⁃Garin S, Poszepczynska⁃Guigné E, et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis[J]. J Invest Dermatol, 2006, 126(2): 272⁃276. DOI: 10.1038/sj.jid.5700068.
|
[12] |
Ho YL, Chang YT, Chu YT, et al. Performance of the SCORTEN in Taiwanese patients with Stevens⁃Johnson syndrome and toxic epidermal necrolysis[J]. Dermatologica Sinica, 2010, 28(1): 15⁃20. DOI: 10.1016/S1027⁃8117(10)60002⁃x.
|
[13] |
George SM, Harrison DA, Welch CA, et al. Dermatological conditions in intensive care: a secondary analysis of the Intensive Care National Audit and Research Centre (ICNARC) case mix programme database[J]. Crit Care, 2008, 12 Suppl 1: S1. DOI: 10.1186/cc6141.
|